Curative Biotechnology (OTCMKTS:CTYX) is a California-based life sciences company specializing in the development and deployment of molecular diagnostic tests, digital health solutions, and therapeutic platforms. Founded in early 2020 to address the urgent need for rapid, scalable COVID-19 testing, Curative quickly expanded its service offerings to include a range of infectious disease assays, at-home sample collection kits, and telehealth-enabled clinical support. The company operates multiple CLIA-certified laboratories and leverages proprietary logistics networks to streamline sample collection, processing, and reporting across all 50 U.S. states.
In addition to its core laboratory testing services, Curative has built a robust digital platform that integrates appointment scheduling, electronic medical records, and real-time result delivery. This end-to-end system enables healthcare providers, employers, government agencies, and individual consumers to access on-demand testing for pathogens such as SARS-CoV-2, influenza, HIV, and sexually transmitted infections. By automating key workflows and reducing reliance on third-party vendors, Curative aims to maintain high throughput while controlling costs and turnaround times.
Beyond diagnostics, Curative has ventured into therapeutic development with early-stage research programs focused on antiviral small molecules and monoclonal antibodies. These efforts are supported by partnerships with academic institutions and contract research organizations, positioning the company to pursue regulatory submissions for novel treatments. Curative’s integrated model—combining laboratory services with digital health and R&D—allows it to collect real-world data that can inform clinical trial design and post-market surveillance initiatives.
Led by co-founders Fred Turner (CEO) and Isaac Turner (COO), Curative maintains headquarters in San Diego, California, with additional laboratory and distribution centers in Los Angeles and Dallas. The leadership team draws on expertise in clinical diagnostics, biotechnology scale-up, and health informatics, aiming to expand the company’s footprint both domestically and abroad. As Curative moves beyond its pandemic origins, it continues to explore strategic collaborations and new market opportunities across North America and select international territories.
AI Generated. May Contain Errors.
